Schematic representation of the regulation of NR3C2 by Macrophage Migration Inhibitory Factor (MIF) in pancreatic cancer progression and disease aggressiveness

MIF Drives Pancreatic Cancer Aggressiveness by Downregulating NR3C2

Posted: May 25, 2016

Pancreatic cancer, while relatively rare, is an aggressive disease ranked as the fourth leading cause of cancer-related death in the US. Because most patients are diagnosed at an advanced stage and their tumors resist available treatments, novel therapeutic targets are urgently needed. Macrophage Migration Inhibitory Factor (MIF) is a proinflammatory cytokine that is elevated in pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, and may provide a molecular link between inflammation and cancer, though the mechanism is unknown.

Colon cancer cells

Antisense Oligonucleotide Therapy for Patients with Advanced Cancer

Posted: May 24, 2016

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the U.S. Improvements in therapy have increased the survival of patients with CRC from 10 months to two years, but for patients who stop responding to treatments, such as irinotecan, options for additional therapy are limited. Antisense oligonucleotides (ASOs) may offer advantages over traditional therapies if an appropriate target can be identified.

New Treatment Target Identified for Diffuse Large B-Cell Lymphoma

Posted: May 13, 2016

NCI researchers have identified new therapeutic targets in a common subtype of diffuse large B-cell lymphoma (DLBCL). Drugs that hit these targets, known as SMAC mimetics, are already under clinical development, and the research team hopes to begin testing them in clinical trials of patients with DLBCL.

10 Questions with NIH Senior Investigator Howard Young

Posted: May 13, 2016

Highly talented scientists underlie the innovative biomedical research conducted at the NIH IRP. I asked one of them, Dr. Howard Young, Senior Investigator at the National Cancer Institute’s (NCI) Frederick, Maryland, campus, about how the environment of opportunity, access to resources, and proximity to cutting-edge science influences his work.

Integrated model of BRD4 function: linking cell cycle and transcription

BRD4 Regulates Transcription via Intrinsic HAT Activity

Posted: May 12, 2016

In order to express a gene, its DNA must be accessible to the transcription machinery. This requires chromatin de-compaction, which depends on the addition of acetyl groups to lysine residues on histones, thereby weakening interactions between histones and DNA and between adjacent nucleosomes.

Dr. Ira Daar Appointed Co-Chief of Cancer and Developmental Biology Laboratory

Posted: May 12, 2016

Ira Daar, Ph.D., has been appointed as Co-Chief of CCR’s Cancer and Developmental Biology Laboratory (CDBL).  Learn more about Dr. Daar and his research.

A Different Approach to Explaining Environment and Accident in Causing Cancer

Posted: May 9, 2016

On April 19, Sven Bilke, PhD, staff scientist in the Genetics Branch discussed his new mathematical model at the AACR Annual Meeting, which, he said, can better define the contributions of environment and accidents from cell division to a person’s risk for cancer.

Dr. Linehan to Receive the 2016 Ramon Guiteras Award

Posted: May 9, 2016

The American Urological Association has selected W. Marston Linehan, MD, to be the recipient of the 2016 Ramon Guiteras Award for identification of genes associated with different types of kidney cancer and developing new strategies for their management.  The Ramon Guiteras Award is the Association’s most prestigious honor and is presented annually for outstanding contributions to the art and science of urology.  The presentation was made at the Annual Meeting of the American Urological Association this week.  Learn more about Dr. Linehan and his research.

Norman Coleman Receives 2016 Failla Award

Posted: May 5, 2016

Norman Coleman, M.D., is the 2016 recipient of the Failla Award presented by the Radiation Research Society. The award is given annually to an outstanding member of the radiation research community in recognition of a history of significant contributions to radiation research. Read more about Dr. Coleman and his research.

Yinling Hu, Ph.D. Receives Tenure

Posted: May 5, 2016

Dr. Hu’s research is aimed at identifying critical events occurring at different stages of cancer initiation, progression, and epithelial-mesenchymal transition. Using mouse models, she is focusing on the roles and regulatory mechanisms of IKKα in skin and lung cancer.  Learn more about Dr. Hu and her research.

Pages